GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » EPS (Diluted)

IntelliPharmaCeutics International (TSXV:IPCI) EPS (Diluted) : C$-0.12 (TTM As of Aug. 2023)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International EPS (Diluted)?

IntelliPharmaCeutics International's Earnings per Share (Diluted) for the three months ended in Aug. 2023 was C$-0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Aug. 2023 was C$-0.12.

IntelliPharmaCeutics International's EPS (Basic) for the three months ended in Aug. 2023 was C$-0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Aug. 2023 was C$-0.12.

IntelliPharmaCeutics International's EPS without NRI for the three months ended in Aug. 2023 was C$-0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2023 was C$-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


IntelliPharmaCeutics International EPS (Diluted) Historical Data

The historical data trend for IntelliPharmaCeutics International's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International EPS (Diluted) Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.82 -0.49 -0.18 -0.21 -0.12

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 -0.01 - -0.08

Competitive Comparison of IntelliPharmaCeutics International's EPS (Diluted)

For the Biotechnology subindustry, IntelliPharmaCeutics International's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's PE Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's PE Ratio falls into.



IntelliPharmaCeutics International EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

IntelliPharmaCeutics International's Diluted EPS for the fiscal year that ended in Nov. 2022 is calculated as

Diluted EPS (A: Nov. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-3.892-0)/33.093
=-0.12

IntelliPharmaCeutics International's Diluted EPS for the quarter that ended in Aug. 2023 is calculated as

Diluted EPS (Q: Aug. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.546-0)/33.093
=-0.08

EPS (Diluted) for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (TSXV:IPCI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


IntelliPharmaCeutics International EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines